SG11201702576QA - Pyrimidinones as factor xia inhibitors - Google Patents

Pyrimidinones as factor xia inhibitors

Info

Publication number
SG11201702576QA
SG11201702576QA SG11201702576QA SG11201702576QA SG11201702576QA SG 11201702576Q A SG11201702576Q A SG 11201702576QA SG 11201702576Q A SG11201702576Q A SG 11201702576QA SG 11201702576Q A SG11201702576Q A SG 11201702576QA SG 11201702576Q A SG11201702576Q A SG 11201702576QA
Authority
SG
Singapore
Prior art keywords
pyrimidinones
factor xia
xia inhibitors
inhibitors
factor
Prior art date
Application number
SG11201702576QA
Other languages
English (en)
Inventor
Andrew K Dilger
James R Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Kumar Balashanmuga Pabbisetty
William R Ewing
Yeheng Zhu
Ruth R Wexler
Donald J P Pinto
Michael J Orwat
Ii Leon M Smith
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201702576QA publication Critical patent/SG11201702576QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
SG11201702576QA 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors SG11201702576QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462058316P 2014-10-01 2014-10-01
PCT/US2015/042576 WO2016053455A1 (fr) 2014-10-01 2015-07-29 Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia

Publications (1)

Publication Number Publication Date
SG11201702576QA true SG11201702576QA (en) 2017-04-27

Family

ID=53784023

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702576QA SG11201702576QA (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors
SG10201911652TA SG10201911652TA (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201911652TA SG10201911652TA (en) 2014-10-01 2015-07-29 Pyrimidinones as factor xia inhibitors

Country Status (34)

Country Link
EP (4) EP3293186B1 (fr)
JP (4) JP6462865B2 (fr)
KR (2) KR102269999B1 (fr)
CN (3) CN110734435B (fr)
AR (1) AR101367A1 (fr)
AU (3) AU2015324530B2 (fr)
CA (1) CA2963395C (fr)
CL (1) CL2017000712A1 (fr)
CO (1) CO2017003833A2 (fr)
CY (2) CY1119678T1 (fr)
DK (2) DK3293186T3 (fr)
EA (1) EA031590B1 (fr)
ES (3) ES2963267T3 (fr)
HR (2) HRP20171950T1 (fr)
HU (2) HUE038061T2 (fr)
IL (2) IL251434B (fr)
LT (2) LT3089979T (fr)
MA (1) MA40123A1 (fr)
MX (2) MX2017003695A (fr)
MY (1) MY183987A (fr)
NO (1) NO2721243T3 (fr)
NZ (2) NZ766570A (fr)
PE (2) PE20210922A1 (fr)
PH (2) PH12017500580A1 (fr)
PL (1) PL3089979T3 (fr)
PT (2) PT3293186T (fr)
RS (2) RS56786B1 (fr)
SG (2) SG11201702576QA (fr)
SI (2) SI3089979T1 (fr)
TN (2) TN2018000229A1 (fr)
TW (2) TWI692478B (fr)
UY (1) UY36244A (fr)
WO (1) WO2016053455A1 (fr)
ZA (1) ZA201702478B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
JP6464176B2 (ja) * 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2760821T3 (fr) 2014-01-31 2018-03-10
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
KR102457840B1 (ko) 2014-10-01 2022-10-21 메르크 파텐트 게엠베하 보론산 유도체
NO2721243T3 (fr) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3310777B1 (fr) 2015-06-19 2019-10-09 Bristol-Myers Squibb Company Diamides macrocycliques en tant q'inhibiteurs du facteur xia
CN107849026B (zh) 2015-07-29 2021-01-01 百时美施贵宝公司 携带烷基或环烷基p2′部分的因子xia大环抑制剂
CN114874222A (zh) 2015-07-29 2022-08-09 百时美施贵宝公司 携带非芳族p2,基团的因子xia新大环
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP2019507167A (ja) 2016-03-02 2019-03-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害活性を有するジアミド大員環
MX2018011784A (es) 2016-03-31 2019-02-13 Janssen Pharmaceuticals Inc Derivados de indol sustituidos como inhibidores de la replicacion virica del dengue.
WO2017167953A1 (fr) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
BR112018068956A2 (pt) 2016-04-01 2019-01-22 Janssen Pharmaceuticals Inc derivados do composto indol substituídos como inibidores da replicação viral da dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2018133793A1 (fr) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 Inhibiteur du facteur xia de coagulation sanguine et ses utilisations
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
ES2929667T3 (es) 2017-05-22 2022-11-30 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
US20220144836A1 (en) * 2019-04-11 2022-05-12 Bristol-Myers Squibb Company Novel synthetic options towards the manufacture of (6r,10s)-10-{4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)-pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6h)-one
WO2020210629A1 (fr) * 2019-04-11 2020-10-15 Bristol-Myers Squibb Company Performance améliorée de formulations solides et solubilisées amorphes pour obtenir des concentrations de plasma thérapeutiques
KR20220002966A (ko) * 2019-04-16 2022-01-07 메드샤인 디스커버리 아이엔씨. XIa 인자 억제제로서의 거대고리 유도체
JP7286001B2 (ja) * 2019-07-23 2023-06-02 メッドシャイン ディスカバリー インコーポレイテッド 第ＸＩａ因子阻害剤としての大環状誘導体
WO2021207659A1 (fr) * 2020-04-10 2021-10-14 Bristol-Myers Squibb Company (9r,135s)-13-{4-[5-chloro-2-(4-chloro-1h,2,3-triazol-1-yl)phényl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluorométhyl)-9-méthyl-3,4,7,15-tétraazatricyclo[12.3.1.02·6]octadéca-1(18),2(6),4,14,16-pentaen-8-one
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
WO2022222960A1 (fr) * 2021-04-21 2022-10-27 上海美悦生物科技发展有限公司 Inhibiteur de fxia et composition pharmaceutique, son procédé de préparation et son utilisation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (fr) 1979-11-05 1983-10-05 Beecham Group Plc Dérivés d'enzymes et leur préparation
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
EP1192135A2 (fr) 1999-06-14 2002-04-03 Eli Lilly And Company Composes
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
CA2726702A1 (fr) 2001-09-21 2003-04-03 Bristol-Myers Squibb Company Composes contenant du lactame et leurs derives en tant qu'inhibiteurs du facteur xa
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
CA2789622C (fr) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles utilises en tant qu'inhibiteurs du facteur xia
US9327839B2 (en) 2011-08-05 2016-05-03 General Atomics Method and apparatus for inhibiting formation of and/or removing ice from aircraft components
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
IN2014CN04676A (fr) * 2011-12-21 2015-09-18 Ono Pharmaceutical Co
DK2880026T3 (en) * 2012-08-03 2017-06-06 Bristol Myers Squibb Co DIHYDROPYRIDON-P1 AS A FACTOR XIA INHIBITORS
LT2882734T (lt) 2012-08-03 2016-12-12 Bristol-Myers Squibb Company Dihidropiridonai, kaip xia faktoriaus slopikliai
NO2760821T3 (fr) * 2014-01-31 2018-03-10
JP6464176B2 (ja) * 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 芳香族ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2721243T3 (fr) * 2014-10-01 2018-10-20

Also Published As

Publication number Publication date
UY36244A (es) 2016-01-29
AU2020200376B2 (en) 2021-07-08
HUE052812T2 (hu) 2021-05-28
MA40123A1 (fr) 2017-09-29
LT3089979T (lt) 2017-12-27
TWI769442B (zh) 2022-07-01
EP3828186B1 (fr) 2023-08-23
TW202043228A (zh) 2020-12-01
IL276470B (en) 2021-04-29
TW202310844A (zh) 2023-03-16
PT3293186T (pt) 2020-12-09
PH12017500580B1 (en) 2017-08-30
KR20180126612A (ko) 2018-11-27
IL276470A (en) 2020-09-30
AU2015324530B2 (en) 2019-10-24
JP6462865B2 (ja) 2019-01-30
ZA201702478B (en) 2019-06-26
SI3089979T1 (sl) 2017-12-29
NZ731416A (en) 2024-01-26
MY183987A (en) 2021-03-17
RS61183B1 (sr) 2021-01-29
JP2019069989A (ja) 2019-05-09
KR102269999B1 (ko) 2021-06-25
TN2017000112A1 (en) 2018-07-04
NO2721243T3 (fr) 2018-10-20
EP3828186A2 (fr) 2021-06-02
CN114957255A (zh) 2022-08-30
EA031590B1 (ru) 2019-01-31
PL3089979T3 (pl) 2018-02-28
NZ766570A (en) 2024-01-26
JP2017530157A (ja) 2017-10-12
HRP20171950T1 (hr) 2018-02-23
DK3089979T3 (en) 2018-01-15
DK3293186T3 (da) 2020-12-14
CY1119678T1 (el) 2018-04-04
CN110734435B (zh) 2022-06-07
KR101921436B1 (ko) 2018-11-22
TWI692478B (zh) 2020-05-01
SG10201911652TA (en) 2020-02-27
ES2963267T3 (es) 2024-03-26
MX2020010840A (es) 2020-11-06
CN110734435A (zh) 2020-01-31
CN106795161B (zh) 2019-10-15
IL251434B (en) 2020-08-31
ES2655884T3 (es) 2018-02-22
EP3089979B1 (fr) 2017-10-18
PT3089979T (pt) 2018-01-16
CA2963395A1 (fr) 2016-04-07
EP3828186A3 (fr) 2021-07-28
CY1123663T1 (el) 2022-03-24
EA201790595A1 (ru) 2017-07-31
PH12020500195A1 (en) 2021-02-08
AR101367A1 (es) 2016-12-14
PH12017500580A1 (en) 2017-08-30
EP4286372A3 (fr) 2024-02-21
JP2023134734A (ja) 2023-09-27
PE20210922A1 (es) 2021-05-19
WO2016053455A1 (fr) 2016-04-07
HUE038061T2 (hu) 2018-09-28
AU2020200376A1 (en) 2020-02-06
AU2021245098A1 (en) 2021-10-28
ES2836270T3 (es) 2021-06-24
JP6937734B2 (ja) 2021-09-22
CL2017000712A1 (es) 2017-11-03
EP3293186B1 (fr) 2020-09-23
EP3293186A1 (fr) 2018-03-14
HRP20201927T1 (hr) 2021-02-05
JP2021185182A (ja) 2021-12-09
IL251434A0 (en) 2017-05-29
CO2017003833A2 (es) 2017-07-11
EP3089979A1 (fr) 2016-11-09
KR20170057431A (ko) 2017-05-24
MX2017003695A (es) 2017-05-30
EP4286372A2 (fr) 2023-12-06
PE20170939A1 (es) 2017-07-13
CN106795161A (zh) 2017-05-31
CA2963395C (fr) 2023-03-14
AU2021245098B2 (en) 2023-11-23
LT3293186T (lt) 2020-12-28
RS56786B1 (sr) 2018-04-30
TN2018000229A1 (en) 2019-10-04
JP7317905B2 (ja) 2023-07-31
SI3293186T1 (sl) 2021-01-29
AU2015324530A1 (en) 2017-05-18
BR112017006702A2 (pt) 2017-12-26
TW201613923A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
IL276470B (en) Pyrimidonines as factor xia inhibitors
IL287113A (en) smyd inhibitors
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
IL247018A0 (en) Heterocyclic compound
HK1226398A1 (zh) 作為midh1抑制劑的苯並咪唑-2-胺
SG11201610904UA (en) Syk inhibitors
EP3134408A4 (fr) Inhibiteurs du facteur xia
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
EP3148542A4 (fr) Inhibiteurs du facteur xia
EP3183255C0 (fr) Spiropyrrolidines utiles en tant qu'inhibiteurs de mdm2
EP3104701A4 (fr) Inhibiteurs du factor xia
EP3180327A4 (fr) Inhibiteurs du facteur xia
EP3180317A4 (fr) Inhibiteurs du facteur xia
IL250022A0 (en) New converted pyrimidine compounds
EP3104702A4 (fr) Inhibiteurs du facteur xia
EP3104703A4 (fr) Inhibiteurs du facteur xia
IL285105A (en) Heterocyclic compound
EP3180325A4 (fr) Inhibiteurs du facteur xia
EP3102571A4 (fr) Pyrimidines substituées utiles en tant qu'inhibiteurs de kinase d'egfr-t790m
EP3247354A4 (fr) Inhibiteurs du factor xia
AP2016009506A0 (en) Pyrimidine compound
SG10201913525QA (en) Pyrimidine derivative
GB201418154D0 (en) Inhibitors